Patents by Inventor Darrell Sleep

Darrell Sleep has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200392206
    Abstract: Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.
    Type: Application
    Filed: March 23, 2020
    Publication date: December 17, 2020
    Inventors: Christopher John Arthur Finnis, Joanna Mary Hay, Esben Peter Friis, Jason Cameron, Darrell Sleep
  • Publication number: 20200385442
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: May 22, 2020
    Publication date: December 10, 2020
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Patent number: 10696732
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 30, 2020
    Assignee: ALBUMEDIX, LTD
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20190113519
    Abstract: The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for HSA binding to the FcRn receptor in said animal. In the non-primate animal species, the binding affinity of wild type HSA to the native FcRn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native FcRn. The present invention also relate to animal models which are particularly suitable for assessing pharmacokinetics of human serum albumin variants.
    Type: Application
    Filed: May 7, 2018
    Publication date: April 18, 2019
    Inventors: Jason Cameron, Darrell Sleep, Jan Terje Andersen, Inger Sandlie
  • Patent number: 10233228
    Abstract: The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: March 19, 2019
    Assignee: ALBUMEDIX LTD
    Inventors: Andrew Plumridge, Darrell Sleep, Inger Sandlie, Jan Terje Andersen, Jason Cameron, Leslie Evans, Steven Athwal, Elizabeth Allan, Esben Peter Friis
  • Patent number: 10080785
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: September 25, 2018
    Assignee: NOVOZYMES BIOPHARMA DK A/S
    Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
  • Publication number: 20180265570
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: May 14, 2018
    Publication date: September 20, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180222963
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: January 12, 2018
    Publication date: August 9, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180200346
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Application
    Filed: December 21, 2017
    Publication date: July 19, 2018
    Applicant: Albumedix A/S
    Inventors: David James Ballance, Darrell Sleep
  • Publication number: 20180162925
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: January 12, 2018
    Publication date: June 14, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180105578
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: April 19, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180105818
    Abstract: The present disclosure relates to a method for producing heterologous protein including: (a) providing a host cell comprising a 2 ?m-family plasmid, the plasmid comprising a gene encoding a protein comprising the sequence of a chaperone protein and a gene encoding a heterologous protein; (b) culturing the host cell in a culture medium under conditions that allow the expression of the gene encoding the chaperone protein and the gene encoding a heterologous protein; (c) purifying the thus expressed heterologous protein from the cultured host cell or the culture medium.
    Type: Application
    Filed: July 19, 2017
    Publication date: April 19, 2018
    Applicant: Albumedix A/S
    Inventors: Darrell Sleep, Gillian Shuttleworth, Christopher John Arthur Finnis
  • Publication number: 20180105577
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: April 19, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180105576
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: April 19, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180072792
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: March 15, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Patent number: 9849162
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: December 26, 2017
    Assignee: ALBUMEDIX A/S
    Inventors: David J. Ballance, Darrell Sleep
  • Patent number: 9821039
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acid vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: November 21, 2017
    Assignee: ALBUMEDIX A/S
    Inventors: David J. Ballance, Darrell Sleep
  • Patent number: 9775888
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: October 3, 2017
    Assignee: ALBUMEDIX A/S
    Inventors: David J. Ballance, Darrell Sleep
  • Publication number: 20170081389
    Abstract: Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.
    Type: Application
    Filed: September 29, 2016
    Publication date: March 23, 2017
    Inventors: Christopher John Arthur Finnis, Joanna Mary Hay, Esben Peter Friis, Jason Cameron, Darrell Sleep
  • Patent number: 9555344
    Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilized aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: January 31, 2017
    Assignee: Albumedix A/S
    Inventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, David James Ballance, Darrell Sleep